Drug information : a guide for pharmacists. (Internet resource, 1996) [WorldCat.org]
skip to content
Drug information : a guide for pharmacists. Preview this item
ClosePreview this item
Checking...

Drug information : a guide for pharmacists.

Author: Patrick M Malone; Karen L Kier; John E Stanovich
Publisher: New York ; Toronto : McGraw-Hill.
Series: McGraw-Hill's AccessPharmacy.
Edition/Format:   Website : Document   Continually Updated Resource   Computer File : English
Summary:

Everything pharmacists need to know about managing drug information for better patient outcomes

Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File, Continually Updated Resource
All Authors / Contributors: Patrick M Malone; Karen L Kier; John E Stanovich
OCLC Number: 767567917
Notes: 4e éd., édité par: Patrick M. Malone, Karen L. Kier, John E. Stanovich.
In McGraw-Hill's AccessPharmacy.
Details: Mode d'accès: Web.
Contents: Chapter One. Introduction to the Concept of Medication InformationMary Lea Gora-Harper and J. Russell MayChapter Two. Formulating Effective Responses and Recommendations: A Structured ApproachKarim Anton Calis and Amy Heck SheehanChapter Three. Drug Information ResourcesKelly M. Shields and Elaine BlytheChapter Four. Literature Evaluation I: Controlled Clinical Trial EvaluationMichael Kendrach, Maisha Kelly Freeman, Terri M. Wensel, and Peter J. HughesChapter Five. Literature Evaluation II: Beyond the BasicsPatrick J. Bryant, Karen P. Norris, Cydney E. McQueen, and Elizabeth A. PooleChapter Six. PharmacoeconomicsJames P. Wilson and Karen L. RascatiChapter Seven. Evidence-Based Clinical Practice GuidelinesKevin G. MooresChapter Eight. The Application of Statistical Analysis in the Biomedical SciencesRyan W. Walters and Karen L. KierChapter Nine. Professional WritingPatrick M. MaloneChapter Ten. Legal Aspects of Drug Information PracticeMartha M. RumoreChapter Eleven. Ethical Aspects of Drug Information PracticeLinda K. OhriChapter Twelve. Pharmacy and Therapeutics CommitteePatrick M. Malone, Nancy L. Fagan, Mark A. Malesker, and Paul J. NelsonChapter Thirteen. Drug Evaluation MonographsPatrick M. Malone, Nancy L. Fagan, Mark A. Malesker, Paul J. Nelson, and Linda K. OhriChapter Fourteen. Quality Improvement and the Medication Use ProcessMark A. Ninno and Sharon Davis NinnoChapter Fifteen. Medication Misadventures I: Adverse Drug ReactionsPhilip J. Gregory and Zara Risoldi CochraneChapter Sixteen. Medication Misadventures II: Medication and Patient SafetyKathryn A. CreaChapter Seventeen. Investigational DrugsBambi GrilleyChapter Eighteen. Policy Development, Project Design, and ImplementationStacie Krick EvansChapter Nineteen. Drug Information in Ambulatory CareDebra L. ParkerChapter Twenty. Drug Information and Contemporary Community Pharmacy PracticeMorgan L. Sperry and Patricia A. MarkenChapter Twenty-One. Drug Information Education and TrainingKelly M. SmithChapter Twenty-Two. Pharmaceutical Industry and Regulatory Affairs: Opportunities for Drug Information SpecialistsJean E. Cunningham and Lindsay E. DavisonAppendix 2-1. Drug Consultation Request FormAppendix 2-2. Sample Questions for Obtaining Background Information From RequestorsAppendix 3-1. Performing a PubMed SearchAppendix 3-2. Selected Primary Literatures SourcesAppendix 4-1. Questions for Assessing Clinical TrialsAppendix 5-1. Beyond the Basics: Questions to Consider for Critique of Primary LiteratureAppendix 7-1. New Zealand Guidelines Group (NZGG)Appendix 7-2. National Institute for Clinical Excellence (NICE)Appendix 7-3. National Institute for Clinical Excellence (NICE) Topic Selection CriteriaAppendix 7-4. Study Selection Process-Centre for Reviews and Dissemination (CRD)Appendix 7-5. Study Selection Points-Centre for Reviews and Dissemination (CRD)Appendix 7-6. Data Synthesis-Centre for Reviews and Dissemination (CRD)Appendix 7-7. National Institute for Clinical Excellence (NICE)-Evidence Table Format for Intervention StudiesAppendix 7-8. New Zealand Guidelines Group (NZGG)-Considered JudgmentAppendix 7-9. Guidelines Advisory Committee (GAC) -Levels of Evidence Grades of RecommendationAppendix 7-10. National Institute for Clinical Excellence (NICE) Guideline StructureAppendix 7-11. Scottish Intercollegiate Guidelines Network (SIGN) Consultation and Peer-ReviewAppendix 7-12. Grades of Recommendation Assessment Development and Evaluation (GRADE) System AdvantagesAppendix 7-13. Appraisal of Guidelines Research & Evaluation (AGREE) InstrumentAppendix 7-14. Conference on Guideline Standardization (COGS) ChecklistAppendix 7-15. Implementation StrategiesAppendix 9-1. Question ExampleAppendix 9-2. AbstractsAppendix 9-3. BibliographyAppendix 11-1. Code of Ethics for PharmacistsAppendix 12-1. Pharmacy and Therapeutics Committee ProcedureAppendix 12-2. Formulary Request FormAppendix 12-3. P&T Committee Meeting AttributesAppendix 12-4. Example P&T Committee MinutesAppendix 12-5. Chairperson SkillsAppendix 12-6. Conflict-of-Interest DeclarationAppendix 13-1. Format for Drug MonographAppendix 13-2. Example Drug MonographAppendix 14-1. Comparison of Quality Assurance and Total Quality Management in Health CareAppendix 14-2. Tools Used in Quality ImprovementAppendix 14-3. Examples of Approaches to Quality ImprovementAppendix 14-4. Example of a Quality Improvement Activity PlanAppendix 14-5. Example Report-Prescriber-Specific ResultsAppendix 14-6. Example of MUE ResultsAppendix 14-7. Quality Evaluation: Response to Drug Information RequestAppendix 15-1. Kramer QuestionnaireAppendix 15-2. Naranjo AlgorithmAppendix 15-3. Jones AlgorithmAppendix 15-4. MedWatch FormAppendix 17-1. Investigational New Drug ApplicationAppendix 17-2. Statement of InvestigatorAppendix 17-3. Protocol Medication Economic AnalysisAppendix 17-4. Investigational Drug Accountability RecordAppendix 18-1. High-Alert MedicationsAppendix 18-2. Medication Shortages and BackordersAppendix 19-1. FDA Guidelines for Proper Medication DisposalAppendix 22-1. Response Letter: Drug A-Incidence of Yellow StripesGlossaryAnswers for Case StudiesAnswers for Self-Assessment QuestionsIndex
Series Title: McGraw-Hill's AccessPharmacy.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.

Similar Items

Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.